research use only
Cat.No.S3770
| Related Targets | HDAC Antioxidant ROS IκB/IKK Nrf2 AP-1 MALT NOD |
|---|---|
| Other NF-κB Inhibitors | DCZ0415 Omaveloxolone (RTA-408) BAY 11-7082 (BAY 11-7821) JSH-23 QNZ (EVP4593) Caffeic Acid Phenethyl Ester SC75741 DHA (Dihydroartemisinin) Withaferin A (WFA) Andrographolide |
|
In vitro |
DMSO
: 10 mg/mL
(8.9 mM)
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 1123.21 | Formula | C54H83NaO23 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 20977-05-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Escin sodium salt | Smiles | CC(C(C)OC(=O)C)C(=O)OCC12C3CC(C(C1O)OC2CC4(C3=CCC5C4(CCC6C5(CCC(C6(C)CO)OC7C(C(C(C(O7)C(=O)O)OC8C(C(C(C(O8)CO)O)O)O)O)OC9C(C(C(CO9)O)O)O)C)C)C)(C)C.[Na+] | ||
| Targets/IC50/Ki |
NF-κB
|
|---|---|
| In vivo |
Sodium aescinate (SA) prevents and alleviates acute lung injury induced by oleic acid. It is used as a vasoactive drug in clinical treatment. Topical application of SA can accelerate wound healing significantly marked by compact collagen deposition and newly regenerated epithelial layer. Sodium aescinate (SA) may effectively control and improve wound healing in diabetic rats via its anti-inflammatory and antioxidant activities. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.